BRWA
AKBA icon

B. Riley Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

B. Riley Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$82.4K Hold
43,360
– – ﹤0.01% 1112
2024
Q3 		$57.2K Hold
43,360
– – ﹤0.01% 1234
2024
Q2 		$44.2K Buy
+43,360
New +$53.6K ﹤0.01% 1349
2023
Q2 		– Sell
-13,000
Closed -$7.29K – 1540
2023
Q1 		$7.29K Buy
+13,000
New +$9.93K ﹤0.01% 1499

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

B. Riley Wealth Advisors's AKBA Position: Q4 2024 in Review

B. Riley Wealth Advisors held its Akebia Therapeutics (AKBA) position steady in Q4 2024 at 43,360 shares worth $82.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1112.

B. Riley Wealth Advisors first reported a position in AKBA in Q1 2023 and has held it in 4 quarters since. 121 funds tracked by Wall St. Rank hold AKBA as of Q4 2024.

  • B. Riley Wealth Advisors held 43,360 shares of Akebia Therapeutics worth $82.4K as of Q4 2024.
  • B. Riley Wealth Advisors left its Akebia Therapeutics share count unchanged in Q4 2024.
  • Akebia Therapeutics made up ﹤0.01% of B. Riley Wealth Advisors's portfolio in Q4 2024, its #1112 holding.
  • B. Riley Wealth Advisors first reported a position in Akebia Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • 121 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2024.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2024, filed 25 Feb 2025.